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Abstract: Hepatocellular carcinoma (HCC) is the fi fth most common malignancy worldwide with approximately 500,000 
new cases per year, ranking as the third cause of cancer deaths. Until the very recent past no systemic therapy was available 
for patients with advanced HCC. However, advances achieved in the understanding of the molecular cancer biology and the 
subsequent introduction of molecularly targeted agents have disclosed promising and interesting possibilities for the treat-
ment of this highly vascularized tumor in which the inhibition of angiogenesis is likely to represent the main potential 
therapeutic target. In this regard, sorafenib, an oral multikinase inhibitor endowed with signifi cant activity against several 
tyrosine-kinase receptors involved in blood vessel development, has shown to be very active in the treatment of advanced 
HCC. This review makes a survey of pharmacology, mode of action, pharmacokinetics, clinical value and safety of sorafenib 
when employed in the treatment of advanced HCC.
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Introduction
Hepatocellular carcinoma (HCC) represents one of the leading solid organ malignancies worldwide, 
accounting for 6% of all tumor types. Approximately 60% to 80% of incidence relates to its common 
association with cirrhosis from heavy and long-lasting alcohol consumption, chronic hepatitis virus 
infections (hepatitis B virus [HBV] in Asia and Africa and hepatitis C virus [HCV] in the Western 
countries), and afl atoxin exposure. Consequently, the management of this tumor becomes even more 
diffi cult because of the presence of this underlying liver disease.1,2 Surgery is the mainstay of HCC 
treatment3 but at presentation, more than 80% patients present with multicentric HCC and advanced 
liver disease or comorbidities that restrict the therapeutic measures to BSC.4 As far as the treatment of 
advanced disease is concerned, to date no single agent or combination chemotherapy have demonstrated 
any advantage in terms of both overall survival and quality of life. Also the hepatic arterial infusion and 
chemoembolization, which in some instances resulted in an increase of response rate, did not show any 
benefi t in terms of overall survival.5 Lastly, no treatment has been identifi ed for severe advanced disease 
whose prognosis is very poor and is measured in months.2
In the very recent past, however, the signifi cant advances achieved in the understanding of cell-cycle 
regulation and tumorigenesis have identifi ed new targets for therapeutic intervention and have disclosed 
new and very promising perspectives for the treatment of this disease. In particular, the potential targets 
for HCC include the vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and 
hepatic/c-met signalling pathways. Neovascularization is one of the most important factors and there 
is a close relationship between VEGF expression and HCC vascularization compared to non-cancerous 
liver tissue.6 It has been demonstrated that VEGF is overexpressed in HCC and correlates with a decrease 
in disease-free survival and overall survival, and with an increase of portal-vein invasion which 
are associated with later stage of disease, high grade and poor prognosis. Moreover, it has been observed 
that also Ras mutations are overexpressed in HCC tumors6–8 demonstrated that dual inhibition of Raf and 
VEGFR2 reduces cells growth and vascularization of hepatocellular carcinoma in exper-
imental model.9
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Sorafenib (Nexavar®, Bayer/Onyx), an oral 
mutikinase dual-action inhibitor able to target Raf 
kinase and vascular endothelial growth factor recep-
tors so preventing both tumor cell proliferation and 
angiogenesis, has been extensively studied in HCC. 
Following a series of preclinical and clinical studies 
carried out in this tumor type which clearly dem-
onstrated a high level of activity, the unquestionable 
results of two pivotal randomized phase III clinical 
trials have acknowledged sorafenib as the only and 
the unique drug presently available and recom-
mended for the treatment of advanced HCC.5,10 This 
review summarizes the main characteristics of 
sorafenib running through the series of results 
achieved in the management of HCC.
Pharmacology, Mode of Action 
and Pharmacokinetics of Sorafenib
Due to the lack of understanding of the molecular 
mechanisms underlying tumorigenesis, cytotoxic 
chemotherapy has represented for many years the 
only medical approach to cancer treatment.7 In the 
last decades of the past century, however, advances 
in molecular biology have led to the identifi cation 
and characterization of genetic elements (gene 
mutation, gene amplifi cation and/or overexpression) 
whose normal function is to control cell growth 
and/or differentiation, which, when altered, play 
a fundamental role in human cancer pathogenesis. 
This occurs through the activation of abnormal 
complex signaling networks mainly involving 
growth factors receptors and signal-transduction 
pathways. Consequently, large drug discovery 
programs have been activated and devoted to the 
identifi cation of biologically specifi c therapies able 
to target the cancer-specifi c pathways,1 also in the 
assumption that the new targeted agents, theoreti-
cally sparing normal cells, could provide a higher 
therapeutic index on account of better safety ben-
efi ts over the standard cytotoxic chemotherapy.7
The fi rst proof of concept that gene is a valid 
anticancer target goes back to 1989 when it was 
demonstrated that the disruption of raf1 gene 
inhibits the growth of a large number of human 
tumors: as a consequence of this, the screening of 
drugs with Raf1 kinase inhibitory activity was 
initiated and developed.
Early investigations carried out in cell lines have 
shown that sorafenib directly inhibits downstream 
Raf kinase isoforms (wild-type Raf1, B-Raf and 
mutant b-raf V600E). The subsequent discovery that 
the drug is also able to block the autophosphoryla-
tion of several tyrosine-kinase receptors such as 
VEGFR1, 2 and 3, PDGFR, c-Kit and RET, has led 
to the settlement that sorafenib is a dual-action drug 
capable to inhibit both tumor-cell proliferation and 
tumor angiogenesis.7 It is likely that the mechanism 
of action of this drug has not yet been completely 
elucidated since, as it has been demonstrated in a 
wide range of tumor models, it seems able to 
increase also the rate of apoptosis.11,12
• Sorafenib demonstrated high interpatient PK variability, 
which is not explained by age, race, gender, or body 
weight1
• Safety data at 400 mg bid were acceptable despite the 
interpatient PK variability1
• A moderate-fat meal does not change AUC significantly, 
whereas a high-fat meal reduces AUC by about 30%2
• A fasting state is recommended for administration 
(at least 1 hour before or 2 hours after eating)2 
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Figure 1. Structural formula and pharmacokinetic properties of Sorafenib.
1Moore M, et al. Ann Oncol. 2005;16:1688–1694.
2Clark JW, et al. Clin Cancer Res. 2005;11:5472–5480.
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Starting from the very early stages of the 
disease, HCC appears as a complex heterogeneous 
hypervascular tumor in which the overexpression 
of proangiogenic factors like VEGF, PDGF and 
angiopoietin-2 has been largely demonstrated. 
Experimental studies have shown that targeting 
angiogenesis is a top priority objective in this 
tumor in which vascular endothelial growth factor 
(VEGF) is responsible for the enhancement of 
development and of metastases.13,14 Besides that, 
there is evidence of aberrant activation of several 
signaling cascades such as EGFR, Ras/extracellular 
signal-regulated kinase, phosphoinositol 3-kinase/
mTOR, hepatocyte growth factor/mesenchymal-
epithelial transition factor, Wnt, Hedgehog, and 
apoptotic signaling.8 Additionally, the HCV core 
proteins, frequently involved in cellular transfor-
mation, elicit high basal Raf-1 activity in hepato-
cytes thus increasing the risk of neoplastic 
conversion.15,16 Therefore, on account of its ability 
to inhibit angiogenesis and RAF kinase pathway, 
sorafenib has been identifi ed as a suitable and ideal 
candidate for studies in HCC.
The pharmacokinetic evaluation of sorafenib in 
humans was carried out in 60 patients with advanced 
refractory solid tumors by testing single and 
repeated orally administered doses of the drug 
ranging from 100 to 800 mg bid. Notwithstanding 
an inter-individual variability of the pharmacokinetic 
profi le likely due to different individual levels of 
absorption of the drug and/or of entero-hepatic 
circulation, results showed that there was no dose-
dependent relationship in pharmacokinetic 
parameters when testing the doses of 400, 600 and 
800 mg considered as the therapeutic ones. 
Maximum mean values of AUC and Cmax were 
reached between 2.5 and 12.5 hours following 
the administration of a single dose of 600 mg bid, 
with only marginal differences as compared to 
the dose of 400 mg bid.17 Further increase of 
the dose to 800 mg bid did not result in any increase 
of the AUC0–12 and Cmax values. Substantial 
accumulation of sorafenib in plasma (2.5 to 7-fold) 
has been observed after repeated administrations: 
steady-state plasma concentrations were achieved 
after seven days.17–19
Food intake before dosing slightly modifi es the 
pharmacokinetic parameters: on the contrary, the 
fat content of the meal seems to have some 
infl uence.18,19 Mean AUC and Cmax values are 
reduced of about 29% and 38% respectively when 
sorafenib is administered following a high-fat meal, 
while an increase of about 14% of the AUC and a 
decrease of 17% of Cmax have been observed when 
sorafenib is given with a moderate-fat meal.19
Sorafenib highly binds to plasma proteins 
(99.5%) with a binding affi nity which is linear and 
independent of the drug concentration.19 It primarily 
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Figure 2. Sorafenib targets both tumour-cell proliferation and angiogesis. Wilhelm S, et al. Mol Cancer Ther. 2008;7:3129–40.
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binds to serum albumin and, to a lesser extent, to 
α-globulins, β-globulins and LDL, while does not 
bind to γ-globulins and α1-acetic glycoprotein.20 
Metabolism of sorafenib has been extensively 
evaluated both in in vitro and in vivo studies. 
Evidences coming from in vitro investigations 
carried out on human liver cell microsomes indicate 
that the fi rst oxidative metabolism is primarily 
mediated by CYP3A4. Moreover, evaluations in 
human hepatocytes have also specified that 
sorafenib is metabolized through a glucuronidation 
pathway involving UGT1A9. Sorafenib is a mod-
erate inhibitor of CYP2C19, CYP2D6, CYP3A4, 
CYP2B6, CYP2C8 and CYP2C9, and the evalua-
tion of the in vitro enzyme induction potential of 
sorafenib showed no activation of the CYP2C19 
and CYP23A enzyme activity.
Studies in vivo using radiolabelled sorafenib 
showed that the drug is predominantly excreted 
with feaces (approximately 77%) and in a lower 
proportion by renal route (19%). No data concerning 
the pharmacokinetics in children are presently 
available. As regards to adults, no dose adjustments 
are needed according to age, gender or renal 
impairment.21 On the contrary, ethnicity has shown 
to infl uence the pharmacokinetic parameters: a 
comparison between Japanese patients and Cau-
casian patients indicates that in the former cohort 
AUC values are 45% lower with a signifi cant 
overlapping in the range of exposures observed in 
the two groups.21,22
Effi cacy Studies
Preclinical studies
Notwithstanding sorafenib was initially recog-
nized as a CRAF inhibitor,23 additional studies 
have also demonstrated that it is a potent inhibitor 
of other kinases such as BRAF (wild-type and 
mutant), VEGFR2, VEGFR3, PDGFR-β, FLT3, 
Ret and c-Kit.23,24 This evidence clearly appeared 
in preclinical models where a dose-dependent 
activity against a wide range of tumor types, 
including HCC, in terms of cell-growth inhibitory 
effects, induction of apoptosis, and down-
regulation of the antiapoptotic protein Mcl-1 
through a Raf/MEK/ERK-independent mechanism 
was observed.11,24
As far as HCC is concerned, preclinical studies 
have demonstrated that Raf/MAPK-ERK kinase 
(MEK)/extracellular signal regulated kinase (ERK) 
pathway plays an important role. The over-expression 
of  activated MEK1 in HCC cell lines, which 
enhances tumor growth and survival by preventing 
apoptosis, suggested that targeting the MEK 
signalling pathway could be an appropriate 
approach to the treatment of HCC.25,26 An evaluation 
of the direct effects of sorafenib carried out in vitro 
n.
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in two different HCC cell lines showed that 
sorafenib is endowed with antiproliferative activity 
and induces cell apoptosis in a dose-dependent way. 
In addition, sorafenib also inhibits the MEK and 
ERK phosphorylation. Subsequent evaluations of 
the effects of sorafenib carried out in vivo in mice 
using a xenograft model showed that the drug 
induces a signifi cant and dose-dependent tumor 
growth inhibition achieving partial tumor regres-
sion in about 50% of animals.11 The entirety of these 
evidences provided the rationale for clinical studies 
with sorafenib in human HCC.
Clinical studies
Preliminary remarks
Since in most cases of HCC the concomitant 
presence of cirrhosis substantially affects the 
evaluation of the stage of the disease and, after-
wards, the choice and the outcome of treatment, 
the measure of the extent and severity of hepatic 
dysfunction represents a crucial aspect which 
cannot be left out. Consequently, the TNM cancer 
staging system cannot be considered adequate and 
satisfactory to properly defi ne a situation resulting 
from the concurrence of quite a lot of factors. 
Therefore, several systems for a better defi nition 
of the stage of the disease and prognosis have been 
proposed. Even though in a retrospective analysis 
of patients with advanced HCC carried out by the 
Memorial Sloan-Kettering Cancer Center the CLIP 
(Cancer of the Liver Italian Program) and 
GRETCH (GRoupe d’Etude et de Traitement du 
Carcinoma Hépatocellulaire) scoring systems 
seemed to satisfactorily fulfi ll the requirements for 
a valid defi nition,2 nowadays the Barcelona-Clinic 
Liver Cancer (BCLC) classifi cation, which links 
tumor stage with treatment strategy, has been 
acknowledged and endorsed by AASLD (Ameri-
can Association for the Study of Liver Diseases) 
and EASL (European Association for the Study of 
the Liver) as the standard one for clinical manage-
ment of HCC.3
Another very important aspect, which deserves 
to be clarifi ed and which calls for the choice of 
new more suitable and reliable alternatives so far 
not yet undeniably identifi ed and still matter of 
evaluation and discussion, relates to the assessment 
of tumor response when using the molecularly 
targeted agents. Likewise other targeted agents, 
in all studies carried out with sorafenib in different 
tumor types RECIST (Response Evaluation 
Criteria in Solid Tumors) criteria, which grade the 
tumor response on the basis of the extent of tumor 
shrinkage, have been used: this resulted in a rather 
limited rate of complete and/or partial responses 
and in a striking rate of stable diseases. This goes 
off because the RECIST criteria, originally devel-
oped to assess responses to cytotoxic drugs, are 
not appropriate as indicators of activity of sorafenib 
and of other targeted agents whose mechanism of 
action lies in a block of cell growth without neces-
sarily inducing cell lysis. As a matter of fact, tumor 
scans have shown that most cases graded as stable 
disease on the basis of the lack of tumor shrinking 
represent on the contrary a consistent response to 
treatment as a necrotic area inside the tumor bur-
den, usually spreading from centre to the periphery, 
has developed.
Phase I
Two single-agent phase I trials27 evaluated sorafenib 
at doses ranging from 50 to 800 mg/day in 69 and 
27 patients with a variety of advanced refractory 
solid tumors. Among 6 evaluable patients with HCC, 
2 stable disease lasting 6 months, 1 stable disease 
lasting 1 year and 1 partial response 6 months 
have been observed. Even if the majority of 
patients experienced at least one adverse event, the 
grades of  toxicities were mostly mild to moderate.18
Another phase I single-agent disease-oriented 
trial was carried out in 27 Japanese patients with 
advanced unresectable HCC (Child–Pugh class A 
or B). They received at first a single dose of 
sorafenib of 200 mg (n = 13) or 400 mg (n = 14) 
followed by a 7-day rest period: subsequently, the 
same doses of sorafenib (200 or 400 mg bid) have 
been administered for 28 consecutive days in 
4-week cycles. Out of 27 patients evaluable for 
effi cacy, of whom 10 treated with 200 mg bid and 
11 with 400 mg bid, 1 (4%) achieved a partial 
remission (PR) and 21 (77.8%) had stable disease 
(SD) evaluated according to RECIST criteria. 
Median Time To Progression (TTP) was 4.9 months. 
Median Overall Survival (OS) in all intent-to-treat 
27 patients was 15.6 months. The authors concluded 
that, in Japanese patients with advanced HCC, 
sorafenib at the doses of 200 mg and 400 mg bid 
is generally well tolerated showing a consistent 
anti-tumor activity.22
An open-label, uncontrolled, phase I trial 
evaluating the combination of sorafenib with doxo-
rubicin also showed a good level of effi cacy of 
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this regimen in the treatment of patients with 
advanced HCC.28
Phase II
An open-label, multicentre, phase II trial evaluating 
sorafenib single agent at the dose of 400 mg bid 
continuous dosing was carried out in 137 previously 
untreated patients with advanced, inoperable HCC 
Child–Pugh class A or B. The evaluation of patients 
on the basis of an independent assessment showed 
PR in 3 (2.2%) patients, minor responses in 8 (5.8%) 
and SD lasting for at least 16 weeks in 46 (33.6%). 
Median TTP was 5.5 months and the OS was 
9.2 months.1 The latter fi gure appears particularly 
interesting since it compares favorably with those 
of other studies evaluating combination regimens 
with conventional cytotoxic agents (PIAF [cisplatin, 
interferon alpha-2b, doxorubicin, fl uorouracil] or 
doxorubicin plus cisplatin) in HCC patients2,3 where 
median overall survival rates accounting for 8.9 and 
7.3 months respectively have been reported.1 In 
addition, in a small group of patients (33), pretreat-
ment tumor phosphorylated ERK (pERK) levels 
have been correlated with the TTP: results show 
that patients who had tumors expressing more 
intense pERK staining had also a longer TTP.1
Another phase II, randomized, double-blind, 
placebo-controlled study evaluated the combina-
tion doxorubicin + sorafenib vs doxorubicin + 
placebo in 96 previously untreated patients with 
advanced HCC Child–Pugh class A or B. Patients 
were randomly allocated to receive either doxoru-
bicin (60 mg/m2 every 3 weeks up to six cycles) 
plus sorafenib 400 mg bid (n = 47), or doxorubicin 
plus placebo (n = 49). After six cycles of doxoru-
bicin and in the absence of disease progression 
patients could decide to continue the treatment with 
either sorafenib or placebo alone until disease 
progression, withdrawal or death. Median TTP, the 
primary endpoint, was 8.6 months for patients in 
the doxorubicin + sorafenib arm vs. 4.8 months for 
those in the doxorubicin + placebo arm. Both 
median Progression Free Survival (PFS) (6.9 vs. 
2.8 months, respectively; HR 0.57; p = 0.012) and 
median OS (13.7 vs. 6.5 months, respectively; HR 
0.45; p = 0.0049) were signifi cantly prolonged in 
the doxorubicin + sorafenib group as compared to 
the doxorubicin + placebo group. The Overall 
Response Rate (ORR) was similar in both groups 
(4% vs. 2%, respectively), SD rate achieved in the 
doxorubicin + sorafenib group was 77% vs. 55% 
in the doxorubicin + placebo group. The toxicity 
profi les were similar in the two arms of the study 
and included toxicities commonly seen with single-
agent doxorubicin and sorafenib. Grade 3–4 
toxicities included fatigue (15%) and neutropenia 
(50%) in both arms. Sorafenib-related toxicity 
included grade 3–4 diarrhea (11%) and grade 3–4 
hand-foot syndrome (9%) in the combination arm. 
More left ventricular dysfunctions in the doxoru-
bicin plus sorafenib arm have been observed, 
which accounted for 19% for all grades and 2% 
for grades 3–4.2,29
Phase III
Two pivotal large phase III trials have been carried 
out to defi nitely assess the effi cacy and safety of 
sorafenib in advanced HCC.
The study SHARP (Sorafenib HCC Assessment 
Randomized Protocol) was an international, 
multi centre, randomized, double-blind, placebo-
controlled trial comparing sorafenib 400 mg bid 
continuous dosing vs. placebo in patients with ECOG 
Performance Status 0–2 and Child–Pugh class A 
not previously treated with systemic therapy.5 Six 
hundred-two patients have been randomized and 
enrolled in 121 sites scattered throughout 21 coun-
tries worldwide (Americas, Europe, and Australia/
New Zealand). The primary objectives of the study 
were OS and time to symptomatic progression 
(TTSP), the latter assessed using the Functional 
Assessment in Cancer Hepatobiliary Symptom 
Index Time to Symptom Progression (FSHI-8-TSP) 
scoring system. TTP, disease control rate and safety 
were secondary endpoints. Before randomization, 
patients have been stratifi ed according to geo-
graphical region, ECOG Performance Status (0 vs. 
1–2) and tumor burden (presence vs. absence of 
macroscopic vascular invasion and/or extrahepatic 
spread). Overall, 299 patients have been random-
ized to receive sorafenib and 303 to receive placebo. 
Approximately 50% of the enrolled patients had 
either hepatitis C virus or hepatitis B virus as 
underlying etiology, and 26% had alcohol related 
cirrhosis. Patients with underlying Child-Pugh class 
A cirrhosis accounted for 95% and 98% in the 
sorafenib and placebo groups, respectively. More 
than 80% of the patients in the sorafenib arm had 
portal vein invasion and were classifi ed as BCLC 
stage C; 20% of them had extra-hepatic metastases. 
Most patients had mild to moderate performance 
status. Based on a planned interim analysis carried 
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out in February 2007 when 321 forecasted events 
occurred, the Data Monitoring Committee (DMC) 
concluded that the trial met the primary endpoint 
since the OS in the group of patients treated with 
sorafenib turned out statistically signifi cant superior 
as compared to the one of patients receiving placebo 
(10.7 months for sorafenib vs. 7.9 for placebo; 
HR = 0.69; p = 0.0005), with a 31% reduction of 
risk of death. The TTP achieved in patients treated 
with sorafenib was almost double as compared to 
the group of patients treated with placebo 
(5.5 months vs. 2.8; HR = 0.58; p  0.001) and also 
the disease control rate (Complete Responses + 
Partial Responses + Stable Diseases 6 weeks) 
was signifi cantly higher in patients treated with 
sorafenib (43 vs. 32%; p = 0.002). As far as 
TTSP is concerned, the study failed to demon-
strate any statistically significant difference 
between sorafenib and placebo (median 4.1 vs. 4.9 
months, respectively; HR = 1.08; p = 0.77); the 
most likely reason for this lack of difference, could 
be ascribable to the reporting of drug-related 
toxicities which may have infl uenced the assess-
ments of the FHSI-8 scoring system, mainly 
because very often it prevented from making a clear 
distinction between drug-related toxicities and 
tumor symptom-related events.5 The DMC also 
underlined the lack of imbalance in the serious 
adverse events rate in the two experimental groups. 
On the light of these results, the DMC stated that 
all patients in the placebo group could have access 
to sorafenib treatment and, on the basis of these 
conclusions, the trial was stopped earlier.
The ASIA-PACIFIC study is an international 
phase III, multicentre, randomized, double-blind, 
placebo-controlled trial which has evaluated 
sorafenib vs. placebo in 226 previously untreated 
patients with advanced HCC or primary liver 
cancer coming from sites across China, Taiwan 
and Korea.
Differently from the SHARP trial, the main 
etiological factors in this study were Asian ethnicity 
and hepatitis B virus. Following stratification 
according to macroscopic vascular invasion and/or 
extra-hepatic spread, ECOG PS and geographic 
region, patients have been randomized in a 2:1 ratio 
either to sorafenib 400 mg bid (n = 150) or to 
placebo (n = 76) treatment. Study endpoints 
included OS, TTP, PFS, TTSP, disease control rate 
(CR + PR + SD  6 weeks) and safety. The primary 
endpoint was not defi ned. Similarly to SHARP 
study, also the ASIA PACIFIC trial showed a 
superiority of sorafenib as compared to placebo in 
terms of OS, PFS, TTP and disease control rate, 
further demonstrating the effi cacy of this drug also 
in patients with different ethnicity and different 
leading etiological factors. Results, reviewed and 
validated by an independent DMC, indicated 
statistically signifi cant differences as regard TTP 
(2.8 months for sorafenib vs. 1.4 for placebo; HR 
0.57; p  0.001), OS (6.5 months vs. 4.2; HR 0.68, 
p = 0.014) and disease control rate (35% [95% CI 
28–44] vs. 16% [95% CI 8–26]). Also in this study 
the TTSP evaluation of the two experimental 
groups did not show any statistically signifi cant 
difference (3.5 months for sorafenib vs. 3.4 for 
placebo; HR = 0.90; p = 0.498).10 The observation 
that the absolute benefi t in the ASIA PACIFIC 
study was smaller as compared to SHARP trial 
could be explained by the fact that patients in the 
oriental trial showed a poorer performance status 
and more advanced tumor stage as exemplifi ed by 
a higher rate in extra-hepatic spread.
Safety
Similar rates of drug-related adverse events in 
terms of both incidence and category, the most 
common being represented by dermatological, 
constitutional and gastrointestinal symptoms, 
have been observed in the phase II and phase III 
studies carried out in patients with advanced 
HCC treated with sorafenib1,5,10 In the large open-
label phase II study where 137 patients have been 
treated, no grade 4 drug-related adverse events 
have been observed. As for the grade 3 events 
recorded in 10% of all patients, they accounted 
for 5.1% hand-foot skin reactions (HFSR), 0.7% 
rash/desquamation, 9.5% fatigue, 8.0% diarrhea, 
1.5% anorexia and 0.7% stomatitis.
In the phase III SHARP trial, the overall incidence 
of adverse events of any grade and from any cause 
was 80% in the sorafenib group and 52% in the 
placebo group; they mainly consisted of gastroin-
testinal, constitutional and dermatologic symptoms. 
On the contrary, the overall incidence of serious 
adverse events from any cause was similar in the 
two study groups accounting for 52% in the 
sorafenib group and 54% in the placebo group: in 
relation with the particular features of the disease 
they were mainly represented by hepato-biliary 
events (11% and 9%, respectively), hemorrhagic 
events (9% and 13%), variceal bleeding (2% and 
4%), renal failure (1% and 3%). The most frequent 
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drug-related grade 3 adverse events included 
diarrhea (8% in the sorafenib group vs. 2% in the 
placebo group, p  0.001), HFSR (8% vs. 1%, 
p  0.001), abdominal pain (2% vs. 1%, p = 0.17), 
hypertension (2% vs. 1%, p = 0.28) and cardiac 
ischemia or infarction (3% and 1%). No grade 4 
drug-related adverse events among any of these 
categories have been reported. Grade 3–4 laboratory 
abnormalities occurred with similar frequencies in 
the two study groups, with the exception of grade 3 
hypophosphatemia (11% in the sorafenib group vs. 
2% in the placebo group, p  0.001) and grade 3 
or 4 thrombocytopenia (4% in the sorafenib 
group vs. 1% in the placebo group, p = 0.006).
The drug-related adverse events recorded in the 
ASIA-PACIFIC study are in line in terms of inci-
dence and category with those observed in the 
SHARP study, being the grade 3–4 represented by 
HFRS (11%), diarrhea (6%), fatigue (9%), and 
hypertension (2%).
Worth nothing is the fact that, with exception 
of the hepatobiliary adverse events strictly related 
to the presence of liver disease, all the drug-related 
events appeared in the studies on HCC correspond 
in terms of both incidence and type to those gath-
ered when using sorafenib in other studies in dif-
ferent tumor types such as the treatment of renal 
cell carcinoma e.g. phase III TARGET study.30
It is likely that some adverse events typical of 
sorafenib and of other targeted agents could be 
related to the particular mechanism of action of 
these drugs. Dermatological toxicity, HFRS in 
particular, represents one of the major features 
following the treatment with sorafenib: the mech-
anism of onset has not yet fully understood but 
almost certainly we are dealing with a side effects 
strictly connected with the anti-kinase activity.2,3 
Analysis of cumulative event rate from the phase III 
pivotal studies carried out with sorafenib in all 
tumor types suggests that rash and HFSR usually 
appear during the fi rst 6 weeks of treatment with 
sorafenib and they get worse as the treatment goes 
on.30 Management of these dermatologic toxicities 
may include topical therapies for symptomatic 
relief, temporary treatment interruption and/or drug 
dose modifi cations, or, in case of increase of severity 
or persistence, permanent discontinuation of 
sorafenib.31–33 In rare instances, yellow skin dis-
coloration, mainly on hands and feet, has also been 
observed during sorafenib treatment: however, 
generalized skin discoloration has not been 
reported.34 Also the increase of incidence of arterial 
hypertension seems to be related to the mechanism 
of action of tirosyne-kinase inhibitors: hyperten-
sion has been reported in a fairly considerable 
percentage of patients treated with sorafenib (5% of 
patients treated in the SHARP study and 12% in 
the TARGET study). It occurred early in the course 
of treatment, it was usually mild-to-moderate, and, 
in the majority of cases, it was controlled with 
standard anti-hypertensive therapies.30,35
Also cardiac toxicity seems peculiar of drugs 
targeting tyrosine-kinase patways. In the SHARP 
study, ischemia/infarction was observed in 3% of 
patients treated with sorafenib and in 1% in the 
placebo group: similarly, in the TARGET study, 
the incidence of treatment-emergent cardiac 
ischemia/infarction events was higher in the 
sorafenib group (2.9%) as compared to placebo 
group (0.4%). As regards other signs of cardiac 
toxicity, the incidence of decreases of LVEF values 
following treatment with sorafenib has been very 
little: only in a single patient a drop of 10% of LVEF 
was reported. In the sorafenib safety database, the 
incidence of congestive heart failures is 2%.36
Quality of Life
No data on quality of life of HCC patients treated 
with sorafenib are presently available, mainly on 
account of the fact that a reliable evaluation of this 
parameter in patients bearing this tumor type is 
really extremely diffi cult to carry out. As previ-
ously mentioned, in both phase III pivotal studies 
in HCC5,10 the assessment of the TTSP using the 
FSHI-8-TSP scoring system failed to demonstrate 
any difference between the cohorts of patients 
treated with sorafenib and placebo. Therefore, at 
least for the time being, the only evidences it is 
possible to rely on are the level of tolerability of 
the treatment and its level of acceptance by patients. 
In this regard, data of the SHARP trial, which show 
that the rate of discontinuation of the study drug 
due to adverse events was similar in the two study 
groups (38% vs. 37%), could be taken as a tool to 
indicate that sorafenib is a well tolerated drug 
scarcely affecting the patients’ quality of life.5
Conclusions
To date, sorafenib represents the fi rst and the only 
systemic therapy able to prolong survival in 
patients with advanced HCC: evidences coming 
from pivotal clinical trials led to the approval of 
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this drug by the International Regulatory Authorities 
(FDA and EMEA) as the new reference standard 
treatment for patients with advanced HCC.3 The 
clinical benefi t obtained with sorafenib in HCC 
with a decrease of risk of death of 31% is similar 
in size to the ones obtained using other molecular 
targeted therapies in other tumor types such as 
trastuzumab in breast cancer, bevacizumab in 
colorectal cancer, erlotinib in non-small-cell lung 
cancer, which induced decreases in the hazard of 
death ranging from 25% to 35%.8
Current knowledge leaves unsolved some 
important issues.
It is necessary to increase the Overall Survival 
benefi t highlighted in the phase III trials, though 
an 0.69 HR it is comparable with the above men-
tioned therapies a 3 months increase in survival is 
not changing this disease natural history. Combina-
tion trials with sorafenib and other target agents 
have been planned in advanced HCC.3 It is also 
important to plan sorafenib development in adju-
vant therapy after potentially curative treatments, 
as resection and local ablation, due to the crucial 
need of an adjuvant therapy for high recurrence 
rate in this tumor.3
Another important point, is the lack of prospec-
tive trials on biomarkers for sorafenib . Two retro-
spective analysis from HOPE1 and SHARP5 
exclude VEGFR as possible biomarker; so it is 
diffi cult to understand if a positive correlation 
between sorafenib clinical effect and HCC vascu-
larization exists. A biomarker should anticipate the 
real effi cacy of a drug on a certain patient. This 
should optimize the public health expenditure, 
given the high cost of new biological therapies. 
Searching a good biomarker candidate it is diffi cult 
due to the lack of knowledge of sorafenib mecha-
nism of action in human HCC.
No doubt however that the positive results of 
sorafenib represent an advancement in the care 
of patients for whom no effective therapy was 
previously available: nonetheless, this represents 
only the fi rst step for a further development of this 
drug in advanced disease in combination with 
chemo-embolization or other molecularly targeted 
therapies, and, almost certainly, in the near future 
also in the adjuvant setting in earlier stages of 
disease after surgery.8
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